StockIQ.techSolventum Corporation (SOLV) Stock Analysis
Free AI-powered analysis and research for Solventum Corporation stock
Sector: Healthcare
SOLV snapshot
Data as of 3 Nov 2026 close. Updated daily.
Solventum Corporation scores 64/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 70% of its 52-week range, up 24.2% over the past year. Latest reported figures show a profit margin of 17.3%, return on equity of 34.0% and revenue growth of +2.2%.
What is driving the score
- RSI Neutral: +5
- Strong Downtrend: -9
- MACD Bearish: -8
- Low P/E (10.2): +10
- Good Profit Margin (17.3%): +5
- Weak Liquidity (1.02 Current Ratio): -5
- Excellent ROE (34.0%): +8
- Above MA200: +4
- Healthy Momentum (+24.2% over 1 year): +7
- Low Volume (0.2x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full SOLV report
Solventum Corporation (SOLV) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze SOLV Now →📰 Latest Update
SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds?
Mon, November 2, 2026 at 3:49 PM UTC 3 min read
Solventum Corporation (SOLV) is set to report its Q3 2026 earnings on November 5, with expectations of continued growth in its MedSurg and Dental segments, driven by strong commercial execution and product innovation. However, challenges such as the reversal of ERP-related advance orders, ongoing implementation issues, and tariff pressures may impact growth and margins. The Zacks Consensus Estimate anticipates a decline in earnings to $1.38 per share and a 6% year-over-year drop in revenues to $1.97 billion.